InsiderTrades.com logo
Andrew Gengos net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Andrew Gengos Biography and Net Worth

CFO of Terns Pharmaceuticals

Mr. Gengos is a seasoned finance and corporate strategy executive with 25 years of experience, successfully leading teams in the life sciences and biotechnology industry. Most recently, he served as the Chief Financial Officer of Athira Pharma, Inc. Prior to that, Mr. Gengos was Chief Business Officer at Cyteir Therapeutics, where he led the finance team that took the company public. In addition, Mr. Gengos held Chief Executive Officer roles at ImmunoCellular Therapeutics and Neuraltus Pharmaceuticals, where he provided strategic and financial leadership across multiple therapeutic areas, including oncology and neurodegenerative disease. Earlier, Mr. Gengos was Vice President of Strategy and Corporate Development at Amgen for eight years. Mr. Gengos started his career at Morgan Stanley before moving on to McKinsey & Co., where he advanced from Associate to Senior Engagement Manager. Mr. Gengos holds an M.B.A. from the UCLA Anderson School of Management and a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.

What is Andrew Gengos' net worth?

The estimated net worth of Andrew Gengos is at least $678.25 thousand as of June 27th, 2025. Mr. Gengos owns 25,000 shares of Terns Pharmaceuticals stock worth more than $678,250 as of December 4th. This net worth evaluation does not reflect any other assets that Mr. Gengos may own. Learn More about Andrew Gengos' net worth.

How do I contact Andrew Gengos?

The corporate mailing address for Mr. Gengos and other Terns Pharmaceuticals executives is 1065 EAST HILLSDALE BLVD. SUITE 100, FOSTER CITY CA, 94404. Terns Pharmaceuticals can also be reached via phone at 650-525-5535 and via email at [email protected]. Learn More on Andrew Gengos' contact information.

Has Andrew Gengos been buying or selling shares of Terns Pharmaceuticals?

Andrew Gengos has not been actively trading shares of Terns Pharmaceuticals during the last ninety days. Most recently, on Friday, June 27th, Andrew Gengos bought 10,000 shares of Terns Pharmaceuticals stock. The stock was acquired at an average cost of $3.93 per share, with a total value of $39,300.00. Following the completion of the transaction, the chief financial officer now directly owns 25,000 shares of the company's stock, valued at $98,250. Learn More on Andrew Gengos' trading history.

Who are Terns Pharmaceuticals' active insiders?

Terns Pharmaceuticals' insider roster includes Amy Burroughs (CEO), Andrew Gengos (CFO), Melita Jung (Insider), Emil Kuriakose (Insider), Hongbo Lu (Director), and Jill Quigley (Director). Learn More on Terns Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Terns Pharmaceuticals?

In the last year, Terns Pharmaceuticals insiders bought shares 5 times. They purchased a total of 63,764 shares worth more than $297,042.68. In the last year, insiders at the sold shares 9 times. They sold a total of 63,938 shares worth more than $665,822.98. The most recent insider tranaction occured on November, 4th when Director Jill M Quigley sold 24,520 shares worth more than $441,360.00. Insiders at Terns Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Terns Pharmaceuticals.

Information on this page was last updated on 11/4/2025.

Andrew Gengos Insider Trading History at Terns Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/27/2025Buy10,000$3.93$39,300.0025,000View SEC Filing Icon  
6/16/2025Buy5,000$3.95$19,750.0015,000View SEC Filing Icon  
6/13/2025Buy10,000$3.73$37,300.0010,000View SEC Filing Icon  
See Full Table

Andrew Gengos Buying and Selling Activity at Terns Pharmaceuticals

This chart shows Andrew Gengos's buying and selling at Terns Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Terns Pharmaceuticals Company Overview

Terns Pharmaceuticals logo
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology, metabolic dysfunction-associated steatohepatitis (MASH), and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of MASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Read More

Today's Range

Now: $27.13
Low: $26.53
High: $28.17

50 Day Range

MA: $15.69
Low: $7.50
High: $29.34

2 Week Range

Now: $27.13
Low: $1.87
High: $29.51

Volume

3,624,545 shs

Average Volume

3,266,852 shs

Market Capitalization

$2.44 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A